ClinicalTrials.gg
RecruitingNCT06953466Updated Aug 31, 2026

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

A Phase 2/3 interventional study of QRX003, 4% Lotion in Netherton Syndrome, sponsored by Quoin Pharmaceuticals. Recruiting at 1 site in United States. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Quoin Pharmaceuticals · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Netherton Syndrome with a site in United States — 4 open to participants now, 6 under way, 4 of them phase 3. Netherton Syndrome · United States.

Planned enrollment
10th of 12
8 · median 20
Started
2025
the only one that year
Phase 2/3
5 of 14
3 open now
Registered
13th of 14
by date
Lead sponsor
4 of 14
Quoin Pharmaceuticals

Among the 14 studies in Netherton Syndrome with a site in United States, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2/3, and was the 13th registered.

Netherton Syndrome

22 studies on the registry are indexed under Netherton Syndrome; 5 are open to participants now.

Browse Netherton Syndrome studies →

Open to participants now

4 of the 14 studies in Netherton Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Netherton Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Netherton Syndrome with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial (via an expanded access Treatment Protocol) is to learn if QRX003 (an investigational drug) applied topically to the skin (including up to the entire body [except the scalp]) works to treat the genetic disease Netherton syndrome. It will also learn about the safety of QRX003. The main questions the trial aims to answer are:

  1. Does QRX003 impact the clinical presentation of NS in adults and minors by improving the clinical symptoms (diseased skin area, itch, and discomfort; based on clinical scoring, subject self-assessment, and other criteria)?
  2. What medical problems do participants have when taking QRX003?
  3. What percent of subjects will require rescue therapy?

Participants will:

Take drug QRX003 twice daily (applied topically to all affected areas of the body excluding the scalp) for 3 months, visit the clinic once every 4-6 weeks for checkups and tests, and to keep a dosing diary that records the times they applied the drug.

03

Conditions studied

  • Netherton Syndrome

Browse trials for

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or non-pregnant female at least 14 years of age.
  2. Females must be , surgically sterile , or use an effective method of , for the duration of the study and for 3 months following completion of treatment. Women of (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Screening and Visit 2/Baseline.
  3. Subject has a clinical diagnosis of NS and agrees to genetic testing at Visit 1/Screening for confirmation of NS diagnosis if the subject does not have test results confirming a SPINK5 mutation.
  4. Subject is in good general health and free of any disease state or physical condition that might impair evaluation of NS or exposes the subject to an unacceptable risk by study participation.
  5. Subject is on a stable treatment regimen including topical therapy for NS prior to baseline that is expected to remain stable for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
  2. Subject has any skin pathology in the Treatment Area or condition that, could interfere with the evaluation of the test article or requires use of interfering topical, systemic, or surgical therapy.
  3. Subject has active cancer of any type excluding non-melanoma skin cancer outside of the Treatment Area.
  4. Subject has diabetes of any type, except non-insulin dependent diabetes mellitus that is reasonably controlled.
  5. Subject has evidence of active infection during screening, or serious infection within 30 days prior to Visit 2/Baseline.
  6. Subject has known , or C virus, or active or latent tuberculosis.
  7. Subject has used ultraviolet phototherapy within the Treatment Area within 10 weeks prior to Visit 2/Baseline.
  8. Subject has used topical prescription treatment in the Treatment Area within 10 weeks prior to Visit 2/Baseline.
  9. Subject has used any topical prescription treatments in the Treatment Area within 10 weeks prior to Visit 2/Baseline.
  10. Subject is currently enrolled in an drug, biologic, or device study.
  11. Subject has used an investigational drug, biologic, or device treatment within 30 days prior to Visit 2/Baseline.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    QRX003, 4% BID

    Subjects will apply test article twice daily (BID) for 12 weeks

    Drug: QRX003, 4% Lotion

Interventions

  • DrugQRX003, 4% Lotion

    Drug page: QRX003

    QRX003 Topical Lotion containing 4% active drug (serine protease inhibitor)

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with 1-point reduction on IGA

    Description: Proportion of subjects with 1-point reduction on the Investigator's Global Assessment (IGA) from Baseline. The IGA assesses overall severity of a subject's NS based on a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.

    Time frame: Up to week 16

Other outcomes

  1. Proportion of subjects with 2-point reduction on IGA

    Proportion of subjects with 2-point reduction in IGA from Baseline.

    Time frame: Up to week 16

  2. NS surface area change

    Change from Baseline in total Body Surface Area (BSA) affected by NS in the Treatment Area

    Time frame: Up to week 16

  3. WI-NRS score change

    Change from Baseline in the Worst Itch-Numeric Rating Scale (WI-NRS) score ≥4. Itch severity is graded on an 11-point scale where 0 represents "no itch" and 10 represents "worst itch imaginable".

    Time frame: Up to week 16

  4. Safety Assessment-AEs

    Any local and systemic AEs (Adverse Events)/serious AEs

    Time frame: Up to week 16

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
May 1, 2025
StartActual
Oct 6, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06953466
Lead sponsor
Quoin Pharmaceuticals
Responsible party
Sponsor
First posted
May 1, 2025
Start date
Oct 6, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 31, 2026

Study contacts

TI Clinical Research
Contact
clinicalresearch@therapeuticsinc.com
858-571-1800 ext. 147
Oleg G Khatsenko
Contact
okhatsenko@therapeuticsinc.com
858-571-1800 ext. 166

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QRX003

Start the discussion